News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Overall survival data indicates that PledOx® does not negatively interfere with the anticancer effect of chemotherapy

December 20, 2016

PledPharma AB
Company Announcement

Overall survival data indicates that PledOx® does not negatively interfere with
the anticancer effect of chemotherapy

Stockholm, 2016-12-20 08:30 CET (GLOBE NEWSWIRE) -- 
PledPharma today announces overall survival data from the Phase IIb study
PLIANT with PledOx® - a drug candidate that reduces the incidence of
chemotherapy induced nerve damage. The 20-month follow-up indicates that
PledOx® does not appear to impact the anticancer effect of chemotherapy and
patient survival rates negatively. 

The follow-up data presented today is based on a comparison of the proportion
of surviving patients in each treatment arm, 20 months after inclusion into the
study.  No difference in overall survival was noted between the patients who
received PledOx® and those who received placebo. There was also no indication
of any difference in survival between the different doses of PledOx® included
in the study. 

It can therefore be concluded that treatment with PledOx® does not appear to
negatively affect the efficacy of the cancer therapy. This conclusion is
supported by tumor measurements carried out during chemotherapy, as well as
previous data on progression-free survival reported at 12 months after
completion of treatment. 

"There is a great need to reduce the incidence of nerve damage that all too
often affects patients treated with chemotherapy. The results presented today
strengthen our conviction that PledOx® has the potential to significantly
improve the treatment of tumor diseases," said Sten Nilsson, Professor of
Oncology and Board member of PledPharma. 

"PledOx® is the first drug candidate shown to prevent chemotherapy induced
nerve damage in a clinically meaningful way without negatively interfering with
the cancer treatment. With these positive results from the PLIANT study, we are
now looking forward to taking the project through the final phase III studies,"
said Jacques Näsström, CEO, PledPharma. 

For more information, please contact:

Jacques Näsström, CEO, phone: +46 737 130 979

Michaela Gertz, CFO, phone: +46 709 26 17 75

About PledPharma

PledPharma develops new drugs that protect the body against oxidative stress –
a potentially debilitating and sometimes life-threatening condition that can be
caused by chemotherapy treatment and following acetaminophen (paracetamol)
overdose. The company's most advanced project PledOx® reduces nerve damage
associated with chemotherapy and positive results from the Phase IIb study
PLIANT were presented during the spring of 2015. The drug candidate Aladote® is
being developed to reduce the risk of acute liver failure associated with
acetaminophen poisoning. 

PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the
company’s Certified Adviser (tel +46 8 463 80 00). For more information, see 

This information is information that PledPharma AB (publ) is obliged to make
public pursuant to the EU Market Abuse Regulation and the Securities Markets
Act. The information was submitted for publication, through the agency of the
contact person set out above, at CET 8:30 on December 20 2016.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10